Aranesp is approved to treat anaemia associated with chronic kidney disease. In July 2002, it was also given approval for weekly dosing for the treatment of anaemia in patients with nonmyeloid ...

This leaflet answers some common questions about Aranesp (darbepoetin alfa). It does not contain all the available information. It does not take the place of talking to your doctor, nurse or ...

Sometimes no news is good news. That seems to be the case for Amgen Inc., which Thursday disclosed top-line Phase III data showing that Aranesp (darbepoetin alfa) did not raise safety concerns in ...

A new study raises fresh safety concerns about widely used anemia medicines, finding that the drug Aranesp nearly doubled the risk of stroke in people with diabetes and chronic kidney problems who are ...

A new study raises fresh safety concerns about widely used anemia medicines, finding that the drug Aranesp nearly doubled the risk of stroke in people with diabetes and chronic kidney problems who are ...

NEW YORK, Feb 16 (Reuters) - Amgen Inc.'s multibillion-dollar anemia drug Aranesp is facing further safety concerns after a medical newsletter reported on Friday that a Danish study of the drug in ...

LOS ANGELES (Reuters) - Amgen Inc. said on Monday that 48.5 percent of cancer patients not undergoing chemotherapy or radiation who received its anemia drug Aranesp in a clinical trial died compared ...

Amgen shares fell 2% Friday after the company disclosed that an independent study of its lucrative anemia drug Aranesp was halted in October because researchers linked it to a higher recurrence of ...

SAN FRANCISCO (MarketWatch) - Shares of Amgen Inc. ended Thursday's session with gains after results of a widely anticipated clinical trial showed that the risk of death didn't increase in lung cancer ...

WASHINGTON, Feb. 20 (UPI) -- Amgen shares slipped Friday after it was revealed a trial involving Aranesp was halted early due to an increased risk of recurrence of tumors in cancer patients, but some ...

A new study raises fresh safety concerns about widely used anemia medicines, finding that the drug Aranesp nearly doubled the risk of stroke in people with diabetes and chronic kidney problems who are ...

A new study raises fresh safety concerns about widely used anemia medicines, finding that the drug Aranesp nearly doubled the risk of stroke in people with diabetes and chronic kidney problems who are ...